To the best of our knowledge, with inclusion of 15 additional studies that were absent in the two previous meta-analysis, the current meta-analysis is the most comprehensive study that has evaluated the association of PARP1 Val762Ala polymorphism with overall cancer risk. Here, PARP1 is linked to cancer.